Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video By: Newsfile November 08, 2022 at 11:00 AM EST Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF) – The company is focused on the disease area of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease. Algernon was recently granted permission to conduct a Phase 1 clinical study of DMT for the treatment of stroke.If you cannot view the video above, please visit:https://www.b-tv.com/post/cse-agn-algernon-pharmaceuticals-advancing-dmt-into-a-phase-1-clinical-trial-btv-ceo-clips-60sec Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF) https://algernonpharmaceuticals.com/ About CEO Clips:CEO Clips – are short company video profiles broadcast to a large audience of investors on TV and 15+ financial sites including Reuters, Yahoo!Finance, and Wall Street Journal.BTV – Business Television/CEO ClipsDiscover Companies to Invest inwww.b-tv.comContact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/143122 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video By: Newsfile November 08, 2022 at 11:00 AM EST Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF) – The company is focused on the disease area of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease. Algernon was recently granted permission to conduct a Phase 1 clinical study of DMT for the treatment of stroke.If you cannot view the video above, please visit:https://www.b-tv.com/post/cse-agn-algernon-pharmaceuticals-advancing-dmt-into-a-phase-1-clinical-trial-btv-ceo-clips-60sec Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF) https://algernonpharmaceuticals.com/ About CEO Clips:CEO Clips – are short company video profiles broadcast to a large audience of investors on TV and 15+ financial sites including Reuters, Yahoo!Finance, and Wall Street Journal.BTV – Business Television/CEO ClipsDiscover Companies to Invest inwww.b-tv.comContact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/143122
Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF) – The company is focused on the disease area of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease. Algernon was recently granted permission to conduct a Phase 1 clinical study of DMT for the treatment of stroke.If you cannot view the video above, please visit:https://www.b-tv.com/post/cse-agn-algernon-pharmaceuticals-advancing-dmt-into-a-phase-1-clinical-trial-btv-ceo-clips-60sec Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF) https://algernonpharmaceuticals.com/ About CEO Clips:CEO Clips – are short company video profiles broadcast to a large audience of investors on TV and 15+ financial sites including Reuters, Yahoo!Finance, and Wall Street Journal.BTV – Business Television/CEO ClipsDiscover Companies to Invest inwww.b-tv.comContact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/143122